Cuba shares lung cancer vaccine with US, trial starts soon

Photo Credit: Global Post

NEW YORK, USA – With recent development in relations between United States and Cuba, Americans will soon enjoy the benefit of a new breakthrough in medicine especially in treatment and prevention of lung cancer, as reported by Daily Mail.

Within the more than five decades rift with US, Cuba had made an impressive advancements in the field of preventative medicine. Among them is a research that successfully developed a therapeutic vaccine that proved to extend the life of patients suffering from lung cancer.

US will definitely benefit with the vaccine as America’s most deadly cancer is lung cancer.

Since 2011, the drug Cimavax has been available to Cuban citizens. Last April, Roswell Park Cancer Center of Buffalo, in New York signed an agreement with Cuba’s Center for Molecular Immunology (CIM) to develop a vaccine for Americans. The clinical trial for the vaccine will be implemented in the United States.

Photo Credit: Wired
Photo Credit: Wired

“The chance to evaluate a vaccine like this is a very exciting prospect,” says Candace Johnson, the CEO of Roswell Park.

“They’ve had to do more with less, so they’ve had to be even more innovative with how they approach things. For over 40 years, they have had a preeminent immunology community,” Johnson said explaining how Cuba was able to formulate the drug, as reported by USA Today.

Johnson said she is excited for the vaccine’s relatively low toxicity and low cost to produce and store, as reported by Wired.

According to report, the vaccine is so cheap that it costs the Cuban government just $1 per shot, the reason why it is free to Cuban patients.

Other than a vaccine, research also suggest that the drug will work effectively for those patients who have not responded to other treatments. Last 2008, a trial of Cimavax showed patients who received the vaccine lived on average four to six months longer.